Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

  • Nutrition (JP Foreyt, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Look AHEAD (Action for Health in Diabetes) was a randomized controlled trial that examined the impact of long-term participation in an intensive weight loss intervention on cardiovascular disease (CVD) morbidity and mortality in people with type 2 diabetes (T2D). The results from this trial suggest that intensive lifestyle interventions are effective in helping patients to achieve management of cardiovascular risk factors and reducing the need to initiate medication usage to manage these conditions, though the benefits in terms of the prevention of CVD morbidity and mortality beyond those achieved through aggressive medical management of hypertension and dyslipidemia is not clear. Additional benefits of participation in an intensive lifestyle intervention such as lowered chronic kidney disease risk, blood pressure, medication usage, improved sleep apnea, and partial remission of diabetes are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997;96(9):3248–50.

    Article  CAS  PubMed  Google Scholar 

  2. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. Impact of obesity on cardiovascular disease. Med Clin North Am. 2011;95(5):919–37.

    Article  PubMed  Google Scholar 

  3. Schelbert KB. Comorbidities of obesity. Prim Care. 2009;36(2):271–85.

    Article  PubMed  Google Scholar 

  4. Smith Jr SC, Collins A, Ferrari R, et al. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). J Am Coll Cardiol. 2012;60(22):2343–8.

    Article  PubMed  Google Scholar 

  5. World Health Organization. Cardiovascular disease: global atlas on cardiovascular disease prevention and control. Geneva, Switzerland: WHO; 2012

  6. International Diabetes Federation. Diabetes atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013

  7. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation. 1996;93(7):1372–9.

    Article  CAS  PubMed  Google Scholar 

  8. Shaper AG, Wannamethee SG, Walker M. Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men. BMJ. 1997;314(7090):1311–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range. JAMA. 1995;273(6):461–5.

    Article  CAS  PubMed  Google Scholar 

  10. Rimm EB, Stampfer MJ, Giovannucci E, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995;141(12):1117–27.

    CAS  PubMed  Google Scholar 

  11. Spataro JA, Dyer AR, Stamler J, Shekelle RB, Greenlund K, Garside D. Measures of adiposity and coronary heart disease mortality in the Chicago Western Electric Company Study. J Clin Epidemiol. 1996;49(8):849–57.

    Article  CAS  PubMed  Google Scholar 

  12. Harris TB, Launer LJ, Madans J, Feldman JJ. Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age. BMJ. 1997;314(7097):1791–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–13.

    Article  PubMed  Google Scholar 

  14. Eisenstein EL, Shaw LK, Nelson CL, Anstrom KJ, Hakim Z, Mark DB. Obesity and long-term clinical and economic outcomes in coronary artery disease patients. Obes Res. 2002;10(2):83–91.

    Article  PubMed  Google Scholar 

  15. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292(20):2471–7.

    Article  CAS  PubMed  Google Scholar 

  16. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162–72.

    Article  CAS  PubMed  Google Scholar 

  17. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167(11):1145–51.

    Article  PubMed  Google Scholar 

  18. International Diabetes Federation, Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 2012. Accessed August 20, 2014.

  19. American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31 Suppl 1:S12–54.

    Article  Google Scholar 

  20. Laddu D, Dow C, Hingle M, Thomson C, Going S. A review of evidence-based strategies to treat obesity in adults. Nutr Clin Pract. 2011;26(5):512–25.

    Article  PubMed  Google Scholar 

  21. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86.

    Article  PubMed  Google Scholar 

  22. Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.

    Article  CAS  PubMed  Google Scholar 

  23. Perri MG. Effects of behavioral treatment on long-term weight loss: lessons learned from the Look AHEAD trial. Obesity (Silver Spring). 2014;22(1):3–4.

    Article  Google Scholar 

  24. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring). 2014;22(1):5–13. This study produced long-term clinically meaningful weight loss in patients with type 2 diabetes. The lifestyle modification strategies used in this study may be utilized in the management of other comorbidities of obesity.

    Article  Google Scholar 

  25. Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24(5):610–28.

    Article  PubMed  Google Scholar 

  26. Brancati FL, Evans M, Furberg CD, et al. Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials. 2012;9(1):113–24.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Bray G, Gregg E, Haffner S, et al. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Vasc Dis Res. 2006;3(3):202–15.

    Article  Google Scholar 

  28. Wesche-Thobaben JA. The development and description of the comparison group in the Look AHEAD trial. Clin Trials. 2011;8(3):320–9.

    Article  PubMed  Google Scholar 

  29. Look AHEAD Research Group, Wadden TA, West DS, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006;14(5):737–52.

    Article  Google Scholar 

  30. Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619–26.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Jakicic JM, Jaramillo SA, Balasubramanyam A, et al. Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. Int J Obes (Lond). 2009;33(3):305–16.

    Article  CAS  Google Scholar 

  32. Foy CG, Lewis CE, Hairston KG, et al. Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial. Obesity (Silver Spring). 2011;19(1):83–93.

    Article  Google Scholar 

  33. Stewart TM, Bachand AR, Han H, Ryan DH, Bray GA, Williamson DA. Body image changes associated with participation in an intensive lifestyle weight loss intervention. Obesity (Silver Spring). 2011;19(6):1290–5.

    Article  Google Scholar 

  34. Williamson DA, Rejeski J, Lang W, et al. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med. 2009;169(2):163–71.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Look AHEAD Research Group. Effect of a long-term behavioral weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD randomized clinical trial. Lancet. in press. Chronic kidney disease is a risk factor for heart failure. Participants in the ILI reduced their risk of CKD by 31 % compared to participants in the DSE, which may eventually lead to reduced CVD mortality. It is possible that the Look AHEAD intervention was ended before the long-term health benefits of participation in an intensive lifestyle weight loss treatment could be observed.

  36. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82.

    Article  Google Scholar 

  39. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37 Suppl 1:S14–80.

    Article  Google Scholar 

  40. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes. Diabetes Care. 2004;27 Suppl 1:S65–7.

    PubMed  Google Scholar 

  42. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.

    Article  CAS  PubMed  Google Scholar 

  43. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care. 2007;30(6):1374–83.

    Article  PubMed  Google Scholar 

  44. The Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566–75.

    PubMed Central  Google Scholar 

  45. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–654.

    Article  PubMed  Google Scholar 

  46. Espeland MA, Lewis CE, Bahnson J, et al. Impact of weight loss on ankle-brachial index and interartery blood pressures. Obesity (Silver Spring). 2014;22(4):1032–41.

    Article  Google Scholar 

  47. Clark CE, Campbell JL, Powell RJ. The interarm blood pressure difference as predictor of cardiovascular events in patients with hypertension in primary care: cohort study. J Hum Hypertens. 2007;21(8):633–8.

    Article  CAS  PubMed  Google Scholar 

  48. Clark CE, Campbell JL, Powell RJ, Thompson JF. The inter-arm blood pressure difference and peripheral vascular disease: cross-sectional study. Fam Pract. 2007;24(5):420–6.

    Article  PubMed  Google Scholar 

  49. Clark CE, Campbell JL, Evans PH, Millward A. Prevalence and clinical implications of the inter-arm blood pressure difference: a systematic review. J Hum Hypertens. 2006;20(12):923–31.

    Article  CAS  PubMed  Google Scholar 

  50. Redmon JB, Bertoni AG, Connelly S, et al. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care. 2010;33(6):1153–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. US Department of Health and Human Services. Physical activity and health: a report of the surgeon general. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.

  52. Church TS, LaMonte MJ, Barlow CE, Blair SN. Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med. 2005;165(18):2114–20.

    Article  CAS  PubMed  Google Scholar 

  53. Kesaniemi YK, Danforth Jr E, Jensen MD, Kopelman PG, Lefebvre P, Reeder BA. Dose-response issues concerning physical activity and health: an evidence-based symposium. Med Sci Sports Exerc. 2001;33(6 Suppl):S351–8.

    CAS  PubMed  Google Scholar 

  54. Blair SN, Kohl 3rd HW, Barlow CE, Paffenbarger Jr RS, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA. 1995;273(14):1093–8.

    Article  CAS  PubMed  Google Scholar 

  55. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218–27.

    Article  CAS  PubMed  Google Scholar 

  56. Sigal RJ, Kenny GP, Boule NG, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147(6):357–69.

    Article  PubMed  Google Scholar 

  57. Church TS, Blair SN, Cocreham S, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2010;304(20):2253–62.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Gibbs BB, Brancati FL, Chen H, et al. Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study. Eur J Prev Cardiol. 2014;21(5):608–17.

    Article  PubMed  Google Scholar 

  59. Belalcazar LM, Lang W, Haffner SM, et al. Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. J Lipid Res. 2012;53(12):2726–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Belalcazar LM, Ballantyne CM, Lang W, et al. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011;31(7):1689–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Belalcazar LM, Reboussin DM, Haffner SM, et al. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010;33(11):2297–303.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA. Impact of the Look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012;20(7):1511–8.

    Article  CAS  Google Scholar 

  63. Belalcazar LM, Haffner SM, Lang W, et al. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring). 2013;21(5):944–50.

    Article  CAS  Google Scholar 

  64. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308(23):2489–96. Type 2 diabetes is thought to be an irreversible condition. However, a significant proportion of participants in the ILI achieved partial or complete remission of type 2 diabetes at year 1 and these results remained at year 4. Improvements in blood glucose control are likely to reduce the risk of microvascular complications and subsequently reduce the risk for CVD mortality.

    Article  CAS  PubMed  Google Scholar 

  65. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75(14):894–903.

    Article  Google Scholar 

  66. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–13.

    Article  PubMed Central  Google Scholar 

  67. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ. 2002;324(7353):1577–80.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–12.

    Article  CAS  PubMed  Google Scholar 

  69. Hood RC. It can be done. Diabetes Care. 2003;26(12):3359–60.

    Article  PubMed  Google Scholar 

  70. Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care. 2007;30(10):2478–83.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.

    Article  PubMed  Google Scholar 

  72. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–7.

    Article  CAS  PubMed  Google Scholar 

  73. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. J Appl Physiol. 2005;99(4):1592–9.

    Article  PubMed  Google Scholar 

  74. Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med. 2002;162(8):893–900.

    Article  PubMed  Google Scholar 

  75. Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med. 2005;172(11):1447–51.

    Article  PubMed Central  PubMed  Google Scholar 

  76. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: the Sleep Heart Health Study. Am J Respir Crit Care Med. 2010;182(2):269–77.

    Article  PubMed Central  PubMed  Google Scholar 

  77. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009;6(8):e1000132.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008;31(8):1071–8.

    PubMed Central  PubMed  Google Scholar 

  79. Rice TB, Foster GD, Sanders MH, et al. The relationship between obstructive sleep apnea and self-reported stroke or coronary heart disease in overweight and obese adults with type 2 diabetes mellitus. Sleep. 2012;35(9):1293–8.

    PubMed Central  PubMed  Google Scholar 

  80. Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013;36(5):641–649A.

    PubMed Central  PubMed  Google Scholar 

  81. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66(3):305–15.

    PubMed  Google Scholar 

  82. van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004;66(6):814–22.

    Article  PubMed  Google Scholar 

  83. Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care. 2005;28(6):1339–45.

    Article  PubMed  Google Scholar 

  84. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108(1):2–8.

    Article  CAS  PubMed  Google Scholar 

  85. Rubin RR, Gaussoin SA, Peyrot M, et al. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia. 2010;53(8):1581–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  86. Rubin RR, Peyrot M, Gaussoin SA, et al. Four-year analysis of cardiovascular disease risk factors, depression symptoms, and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetes Care. 2013;36(5):1088–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  87. The Look AHEAD Research Group. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care. 2014;37(6):1544–53.

    Article  Google Scholar 

  88. Faulconbridge LF, Wadden TA, Rubin RR, et al. One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study. Obesity (Silver Spring). 2012;20(4):783–93.

    Article  PubMed Central  Google Scholar 

  89. Rejeski WJ, Bray GA, Chen SH, et al. Aging and physical function in type 2 diabetes: 8 years of an intensive lifestyle intervention. J Gerontol A Biol Sci Med Sci. 2014.

  90. Schwartz AV, Johnson KC, Kahn SE, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res. 2012;27(3):619–27.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the Children’s Nutrition Research Center for their continued support. This research was funded by institutional support from the US Department of Agriculture, Agricultural Research Service (Cooperative Agreement no. 58-6250-6001).

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Craig A. Johnston, Jennette P. Moreno, and John P. Foreyt declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Baylor College of Medicine, USDA/ARS Children’s Nutrition Research Center, Department of Pediatrics-Nutrition and Department of Medicine, 1100 Bates, Houston, TX, 77030, USA

    Craig A. Johnston

  2. Baylor College of Medicine, USDA/ARS Children’s Nutrition Research Center, Department of Pediatrics-Nutrition, 1100 Bates, Houston, TX, 77030, USA

    Jennette P. Moreno

  3. Baylor College of Medicine, Department of Medicine, 6655 Travis, Suite 320, Houston, TX, 77030, USA

    John P. Foreyt

Authors
  1. Craig A. Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennette P. Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John P. Foreyt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Craig A. Johnston.

Additional information

This article is part of the Topical Collection on Nutrition

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Johnston, C.A., Moreno, J.P. & Foreyt, J.P. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. Curr Atheroscler Rep 16, 457 (2014). https://doi.org/10.1007/s11883-014-0457-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-014-0457-6

Keywords

Search

Navigation